HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
JfUFBSdx8bfcQe1q